BioNTech SE (BNTX) EBT (2018 - 2025)
BioNTech SE (BNTX) posted EBT of -$264.7 million for Q4 2025, down 1016.7% sequentially from $28.9 million in Q3 2025, and down 182.24% YoY from $321.9 million in Q4 2024.
BioNTech SE (BNTX) EBT (2018 - 2025) Analysis & Trends
BioNTech SE has reported EBT for 8 years, with the latest figure at -$264.7 million in Q4 2025.
- Quarterly EBT fell 182.24% year-over-year to -$264.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.2 billion (down 58.48% YoY) and the FY2025 annual result came in at -$1.2 billion, down 63.94% from the prior year.
- EBT fell to -$264.7 million in Q4 2025 per BNTX's latest filing, from $28.9 million in the prior quarter.
- Over five years, EBT peaked at $5.6 billion in Q1 2022 and troughed at -$867.8 million in Q2 2024.
- A 5-year average of $1.5 billion and a median of $517.7 million in 2023 frame the typical range for EBT.
- The sharpest annual moves came in 2021 and 2025: EBT surged 2199836406.41% in 2021, then sank 182.24% in 2025.
- Over 5 years, EBT stood at $5.4 billion in 2021, then slumped by 39.98% to $3.2 billion in 2022, then slumped by 77.95% to $713.6 million in 2023, then sank by 54.89% to $321.9 million in 2024, then tumbled by 182.24% to -$264.7 million in 2025.
- According to Business Quant data, EBT over the past three periods registered -$264.7 million, $28.9 million, and -$455.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | -264.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -264.70 Mn |
| Sep 30, 2025 | 28.88 Mn |
| Jun 30, 2025 | -455.84 Mn |
| Mar 31, 2025 | -468.51 Mn |
| Dec 31, 2024 | 321.86 Mn |
| Sep 30, 2024 | 174.29 Mn |
| Jun 30, 2024 | -867.76 Mn |
| Mar 31, 2024 | -360.45 Mn |
| Dec 31, 2023 | 713.56 Mn |
| Sep 30, 2023 | 247.55 Mn |
| Jun 30, 2023 | -448.85 Mn |
| Mar 31, 2023 | 759.60 Mn |
| Dec 31, 2022 | 3.24 Bn |
| Sep 30, 2022 | 2.46 Bn |
| Jun 30, 2022 | 2.47 Bn |
| Mar 31, 2022 | 5.63 Bn |
| Dec 31, 2021 | 5.39 Bn |
| Sep 30, 2021 | 5.50 Bn |
| Jun 30, 2021 | 4.84 Bn |
| Mar 31, 2021 | 1.98 Bn |